MPM BioImpact’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

MPM BioImpact’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-650,000	Closed	-$3.53M	–	34
2022 Q4	$3.53M	Sell	650,000 -206,798	-24%	-$1.73M	0.92%	24
2022 Q3	$10.7M	Hold	856,798	–	–	2.53%	13
2022 Q2	$4.23M	Hold	856,798	–	–	1.18%	23
2022 Q1	$6.51M	Hold	856,798	–	–	1.75%	16
2021 Q4	$8.75M	Sell	856,798 -3,704	-0.4%	-$47.2K	1.59%	17
2021 Q3	$11.5M	Buy	860,502 +47,708	+6%	+$777K	1.79%	14
2021 Q2	$17.8M	Sell	812,794 -115,000	-12%	-$2.55M	2.93%	11
2021 Q1	$22.3M	Sell	927,794 -496,000	-35%	-$11.5M	2.8%	9
2020 Q4	$25.6M	Hold	1,423,794	–	–	4.5%	8
2020 Q3	$16.4M	Hold	1,423,794	–	–	3.96%	9
2020 Q2	$34.5M	Hold	1,423,794	–	–	9.18%	6
2020 Q1	$15.7M	Hold	1,423,794	–	–	9.58%	4
2019 Q4	$37.6M	Buy	+1,423,794	New	+$33.3M	13.34%	4

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MPM BioImpact's GTHX Position: Q1 2023 in Review

MPM BioImpact sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 650,000 shares — an estimated $3.53M sold.

MPM BioImpact first reported a position in GTHX in Q4 2019 and held it in 13 quarters. The position peaked at $37.6M in Q4 2019. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

MPM BioImpact reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
MPM BioImpact sold 650,000 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $3.53M.
MPM BioImpact first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2019 and held it in 13 quarters.
MPM BioImpact's G1 Therapeutics, Inc. Common Stock position peaked at $37.6M in Q4 2019.
96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on MPM BioImpact's 13F filing for Q1 2023, filed 12 May 2023.